Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for ...
Studies highlight efficacy of allogeneic stem cell transplantation in treating relapsed or refractory Hodgkin's lymphoma and large B-cell lymphoma, with reduced-intensity conditioning regimens showing promising results.
Epigenetic drugs show 375% increase in Series A venture financing in 2024
Epigenetic drugs' Series A venture financing doubled, reaching $342m YTD 2024. Moonwalk Biosciences raised $57m in Jan 2024. Marketed drugs like DNMT and HDAC inhibitors show success in blood cancers but have off-target effects. New generation drugs aim for improved specificity. FDA's approval of Vertex's Casgevy in Dec 2023 boosted investor confidence. Avenzo Therapeutics raised $150m in Mar 2024 for CDK2 inhibitor ARTS-021. Challenges include durable gene expression effects and drug delivery.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath